VALHALLA

Fujifilm Introduces First-of-its-Kind Transducer for On-Pump Intracardiac Echocardiography Imaging (OPIE) for Septal Myectomy

Retrieved on: 
Friday, April 26, 2024
FDA, Cardiothoracic surgery, AATS, TTE, Tech, Ventricular septal defect, Heart, Cleveland Clinic, Facial muscles, MD, Doctor of Philosophy, NYU, FACS, Indocyanine green, Cardiology, Fujifilm, OPIE, TEE, Division, Medical imaging

Lexington, MA,, April 26, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced the launch of its first-of-kind OPIE Transducer for on-pump intracardiac echocardiography (OPIE) for septal myectomy.

Key Points: 
  • Lexington, MA,, April 26, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced the launch of its first-of-kind OPIE Transducer for on-pump intracardiac echocardiography (OPIE) for septal myectomy.
  • However, with OPIE, a thin transducer is passed into the heart during the myectomy where images of the patient’s septal thickness can be seen in real-time.
  • A study featuring Fujifilm’s OPIE Transducer highlights that the system provides established imaging to aid in septal myectomy procedures compared to TEE and transthoracic echocardiogram (TTE).
  • Real-time measurements of the interventricular septal thickness are crucial during septal myectomy to avoid creating a ventricular septal defect while resecting enough myocardium.

Fujifilm and Predictive Oncology Announce Collaboration to Reduce Protein Interference in Bacterial Endotoxin Detection Testing of Biopharmaceuticals

Retrieved on: 
Thursday, April 25, 2024
FDA, USP, Inflammation, Bacteria, Death, LPS, Lipopolysaccharide, Patient, LAL, Limulus amebocyte lysate, Gram-negative bacteria, Fujifilm, Fever

Corporation (Fujifilm), a supplier of high purity chemicals and reagents, and Predictive Oncology Inc., (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that the companies have entered into a collaboration and co-marketing agreement to reduce protein interference in bacterial endotoxin testing of biopharmaceutical products.

Key Points: 
  • Corporation (Fujifilm), a supplier of high purity chemicals and reagents, and Predictive Oncology Inc., (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that the companies have entered into a collaboration and co-marketing agreement to reduce protein interference in bacterial endotoxin testing of biopharmaceutical products.
  • Per the terms of the agreement, Predictive Oncology will utilize its novel EndoPrep™ sample treatment technology (EndoPrep), together with Fujifilm’s PYROSTAR™ bacterial endotoxin detection reagent (PYROSTAR), to detect residual endotoxins more accurately in biopharmaceuticals by eliminating protein interference from the drug product in the detection assay.
  • The Limulus Amebocyte Lysate (LAL) test is recognized by the U.S. Pharmacopeia (USP) for determining endotoxin levels in many biopharmaceuticals.
  • *Compared to traditional industry standards of utilizing heat-treatment or dilution to remove the interference of high protein.

Fujifilm to Invest Additional $1.2 Billion to Expand its Large-Scale Cell Culture CDMO Business in North Carolina

Retrieved on: 
Thursday, April 11, 2024
Nitrogen oxide, Fujifilm Diosynth Biotechnologies, Solar energy, Monoclonal antibody, Town, Water, Carbon, Growth, CDMO, Environment, Life, Certification, LEED, Bioreactor, Patient, Gold, Fujifilm, Spacecraft, Renewable energy

TOKYO, April 11, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Corporation today announced an investment of $1.2 billion in its Large-Scale Cell Culture CDMO* Business to further expand the planned FUJIFILM Diosynth Biotechnologies end-to-end bio-manufacturing facility in Holly Springs, North Carolina, bringing the total investment in the facility to over $3.2 billion.

Key Points: 
  • TOKYO, April 11, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Corporation today announced an investment of $1.2 billion in its Large-Scale Cell Culture CDMO* Business to further expand the planned FUJIFILM Diosynth Biotechnologies end-to-end bio-manufacturing facility in Holly Springs, North Carolina, bringing the total investment in the facility to over $3.2 billion.
  • The expansion adds significant large-scale production capacity to FUJIFILM Diosynth Biotechnologies’ global network through its United States and Europe manufacturing hubs.
  • The investment will generate an additional 680 jobs by 2031, also bringing the total number of new, highly skilled local jobs to 1400 in Holly Springs.
  • Over the course of the 12-year term of this grant, the project is estimated to grow the state’s economy by $4.7 billion.

Brainlab and Fujifilm Integrate Cutting-Edge Technology, Offering Advanced Capabilities to Neurosurgery Clinicians in the U.S.

Retrieved on: 
Thursday, April 4, 2024
Element, MRI, Surgeon, Brain, Digital, Patient, Brainlab, Neurosurgery, Neoplasm, Imri, Data, FDA, Health, Medical imaging

ARIETTA Precision , in conjunction with a Brainlab surgical navigation system , becomes a powerful intraoperative neurosurgery solution, delivering advanced guidance and image quality for critical surgical decisions.

Key Points: 
  • ARIETTA Precision , in conjunction with a Brainlab surgical navigation system , becomes a powerful intraoperative neurosurgery solution, delivering advanced guidance and image quality for critical surgical decisions.
  • Together, the systems serve as a deeply integrated end-to-end solution providing comprehensive intraoperative information leveraging the best of both worlds in imaging and navigation.
  • This combined solution is expected to be FDA cleared and available in the United States in mid-2024.
  • * The combination of these technologies provides neurosurgeons with real-time insights through live intraoperative ultrasound (IOUS) during neurosurgical procedures.

Fujifilm to Debut New Products for Broadcast, Cinema, and Digital Content Creators at NAB 2024

Retrieved on: 
Thursday, April 4, 2024
Instrument, Super 35, Fujifilm X series, NAB, Steadicam, Central Hall, Fujifilm, Lens, Sony, National Association, Calendar, NAB Show, Telescopic sight

VALHALLA, N.Y., April 04, 2024 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation’s Electronic Imaging and Optical Devices Divisions will debut a variety of new gear and technology at the 2024 National Association of Broadcasters Show (NAB 2024) from April 14 – 17, 2024 in Las Vegas.

Key Points: 
  • VALHALLA, N.Y., April 04, 2024 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation’s Electronic Imaging and Optical Devices Divisions will debut a variety of new gear and technology at the 2024 National Association of Broadcasters Show (NAB 2024) from April 14 – 17, 2024 in Las Vegas.
  • Duvo™ 25-1000mm was awarded Best Overall Product in the “CREATE” Category of the 2023 NAB Show “Product of the Year” Awards.
  • “The continual excitement around our products is constantly generating conversations and creating new avenues for customers to explore.
  • For more information about Fujifilm's presence at NAB 2024, click here .

Fujifilm Receives 510(k) Clearance for CAD EYE®, New AI-Powered Endoscopic Imaging Technology for Colonic Polyp Detection

Retrieved on: 
Wednesday, March 20, 2024
Colonoscopy, LCI, Documentation, Adenoma, EYE, Colorectal cancer, Conditional sentence, Risk, White Light, Polyp, APC, Assist, AI, Woman, Workflow, System, Safety, Swedish Health Services, Endoscopy, FDA, Health, CAD, Medical device

Lexington, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation , a leading provider of endoscopic imaging and endosurgical solutions, received 510(k) clearance for CAD EYE, the company’s novel AI detection system for endoscopic imaging.

Key Points: 
  • Lexington, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation , a leading provider of endoscopic imaging and endosurgical solutions, received 510(k) clearance for CAD EYE, the company’s novel AI detection system for endoscopic imaging.
  • CAD EYE® enables real-time detection of colonic mucosal lesions such as polyps and adenomas during colonoscopy procedures, supporting endoscopists in their ability to detect and remove pre-cancerous lesions, regardless of size, shape and color.
  • Consisting of a compatible expansion unit (the Fujifilm EX-1) and endoscopy support software (EW10-EC02), CAD EYE is an evolution of Fujifilm’s ELUXEO® Endoscopic Imaging System, featuring AI image processing functionality customized for the integration with the system’s processor and the endoscope.
  • CAD EYE, ELUXEO and LCI are registered trademarks of FUJIFILM Corporation in various jurisdictions.

Tech and Style Converge with Fujifilm’s INSTAX MINI 99™ Instant Camera

Retrieved on: 
Thursday, March 14, 2024
Dark, Smartphone, Friends, App, Mandarin Oriental Hotel Group, Light leak, Sepia, Holiday, CAD, Creativity, Lighting, LED, USD, Camera

VALHALLA, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation today announced the newest introduction to the FUJIFILM INSTAX family of analog instant cameras with the debut of its FUJIFILM INSTAX MINI 99 instant camera (MINI 99).

Key Points: 
  • VALHALLA, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation today announced the newest introduction to the FUJIFILM INSTAX family of analog instant cameras with the debut of its FUJIFILM INSTAX MINI 99 instant camera (MINI 99).
  • Driven by LED lights within the camera, the Color Effect feature exposes the chosen color onto the INSTAX MINI instant film, creating the desired effect on the printed INSTAX MINI image.
  • Smartphone App, FUJIFILM INSTAX users can:
    Import digitally stored photos from other INSTAX Apps (the INSTAX MINI LINK App or the INSTAX LINK WIDE App, for instance) into the INSTAX Up!
  • The INSTAX MINI 99 instant camera is expected to be available in mid-April 2024 at a Manufacturer’s Suggested Retail Price of $199.95 USD and $249 CAD.

FUJIFILM Diosynth Biotechnologies Appoints Richard McAvoy as Chief Financial Officer

Retrieved on: 
Monday, March 11, 2024
CFO, Head, Potyvirus, Life, Growth, Novo Nordisk, Alston & Bird, Vaccine, CDMO, History, Financial management, Small Business Saturday, Partner, Fujifilm Diosynth Biotechnologies, Management

In his new role, McAvoy will be responsible for the Company’s financial strategies, overseeing all financial activities within the organization, ensuring robust financial management and contributing to the realization of FUJFILM Diosynth Biotechnologies’ aggressive growth strategy.

Key Points: 
  • In his new role, McAvoy will be responsible for the Company’s financial strategies, overseeing all financial activities within the organization, ensuring robust financial management and contributing to the realization of FUJFILM Diosynth Biotechnologies’ aggressive growth strategy.
  • We look forward to Richard’s contributions as we execute on our growth strategy," said Lars Petersen, president and chief executive officer of FUJIFILM Diosynth Biotechnologies.
  • Prior to joining FUJIFILM Diosynth Biotechnologies, he held leadership roles at Novo Nordisk and Alston & Bird LLP.
  • To find more information on all members of the FUJIFILM Diosynth Biotechnologies Executive Leadership team please visit: www.fujifilmdiosynth.com/leadership

Fujifilm Demonstrates Commitment to and Investment in Education at the 2024 Healthcare Information and Management Systems Society (HIMSS) Global Conference and Exhibition

Retrieved on: 
Thursday, March 7, 2024
Cloud, Radiology, Architecture, Enterprise imaging, Artificial intelligence, AI, Education, MD, HIMSS, Cardiology, Health, Fujifilm, Organization, URG, VNA, Environment, Miller, AWS, PACS, Synapse

Fujifilm’s KLAS award-winning and government-validated Synapse® Enterprise Imaging solutions will be presented and available for demonstration in booth 4461.

Key Points: 
  • Fujifilm’s KLAS award-winning and government-validated Synapse® Enterprise Imaging solutions will be presented and available for demonstration in booth 4461.
  • These solutions include 7x Enterprise PACS, AI Orchestrator, VNA, EIS/RIS, 3D Advanced Visualization, Enterprise Imaging Analytics, Cloud Services, and Pathology PACS.
  • “Our vision has been laser focused on delivering the best possible enterprise imaging solution to meet our customers' growing needs.
  • “Our team looks forward to demonstrating how Fujifilm’s Synapse Enterprise Imaging portfolio is orchestrating AI and further innovating diagnostic workflows with AI results.

Fujifilm Announces Availability of FUJINON Duvo™ HZK24-300mm Portable PL Mount Zoom Lens: Wide, Light, and Long

Retrieved on: 
Thursday, March 7, 2024
NAB Show, Lens, Fujifilm, Fujinon, Steadicam, NAB, Telescopic sight

VALHALLA, N.Y., March 07, 2024 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation’s Optical Devices Division announces the availability of its new FUJINON Duvo™ HZK24-300mm Portable PL Mount Zoom Lens (”Duvo 24-300mm“).

Key Points: 
  • VALHALLA, N.Y., March 07, 2024 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation’s Optical Devices Division announces the availability of its new FUJINON Duvo™ HZK24-300mm Portable PL Mount Zoom Lens (”Duvo 24-300mm“).
  • Fujifilm expects to begin shipping initial orders of Duvo 24-300mm to customers at the end of March, 2024.
  • This versatile portable lens can be used with a tripod, shoulder-mounted with a Steadicam [2] , or for high-angle shooting, using a crane.
  • Complementing the previously released FUJINON Duvo™ HZK25-1000mm F2.8-F5.0 PL Mount Cinema Box Lens (“Duvo 25-1000mm”) — Fujifilm’s first Duvo Series lens — Duvo 24-300mm delivers 12.5x zoom, covering the frequently used 24-300mm focal range.